Nurix Therapeutics to Participate in Upcoming Investor Conferences
Nurix Therapeutics (NRIX) announced that company management will participate in fireside chats at three upcoming investor conferences.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Nurix Therapeutics (NRIX) announced that company management will participate in fireside chats at three upcoming investor conferences.
The chats are scheduled for the UBS Global Biopharma Conference on November 17, 2026, at 2:40 p.m. GMT; the Jefferies Global Healthcare Conference on November 18, 2026, at 11:00 a.m. GMT; and the Piper Sandler Annual Healthcare Conference on December 2, 2026, at 3:30 p.m. ET. Live webcasts will be available through the Investors section of Nurix’s website, with archives available for 30 days after each event.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BRISBANE, Calif., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced that Company management will participate in fireside chats at the following investor conferences:
- UBS Global Biopharma Conference
Tuesday, November 17, 2026, at 2:40 p.m. GMT - Jefferies Global Healthcare Conference
Wednesday, November 18, 2026, at 11:00 a.m. GMT - Piper Sandler Annual Healthcare Conference
Wednesday, December 2, 2026, at 3:30 p.m. ET
The fireside chats will be webcast live and may be accessed on the Investors section of the Nurix website, where they will be archived for 30 days after the event.
About Nurix Therapeutics, Inc.
Nurix Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, a new frontier in drug discovery aimed at improving treatment options for patients with cancer and autoimmune diseases. Nurix’s clinical-stage oncology pipeline includes bexobrutideg, a degrader of BTK being co-developed with Roche, and NX-1607, an inhibitor of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), an E3 ligase that regulates activation of multiple immune cell types including T cells and NK cells. Nurix’s autoimmune disease pipeline includes bexobrutideg in collaboration with Roche and a clinical-stage degrader of IRAK4 in collaboration with Gilead. Nurix is also advancing multiple potentially first-in-class or best-in-class degraders and degrader antibody conjugates in its wholly owned preclinical pipeline and under collaboration agreements with Gilead Sciences, Inc., Sanofi S.A. and Pfizer Inc., within which Nurix retains certain options for co-development, co-commercialization and profit sharing in the United States for multiple drug candidates. Powered by an AI-integrated discovery engine capable of tackling virtually any protein class and coupled with unparalleled ligase expertise, Nurix has built a formidable advantage in translating the science of targeted protein degradation into clinical advancements. Nurix aims to efstablish degrader-based treatments at the forefront of patient care, writing medicine’s next chapter with a new script to outmatch disease. Nurix is headquartered in Brisbane, California. For additional information, visit www.nurixtx.com.
Contacts:
Media & Investors
Kris Fortner
Nurix Therapeutics, Inc.
kfortner@nurixtx.com
